
Metsera Inc (MTSR) Stock Forecast & Price Target
Metsera Inc (MTSR) Analyst Ratings
Bulls say
Metsera Inc. is positioned favorably due to its development of highly selective biased agonists that do not activate β-arrestin, allowing for improved safety and tolerability through the potential use of lower doses. The company's ongoing clinical trials for its dual-agonist peptide profile indicate promising early results, with a 14% placebo-adjusted weight loss (WL) observed in the MET-097i study, reinforcing confidence in achieving a target of at least 13% WL in the upcoming VESPER-1 trial. Additionally, Metsera's advanced proprietary technologies and methods enhance the scalability and versatility of its NuSH analog peptide portfolio, contributing to a comprehensive strategy aimed at addressing key limitations seen in existing obesity therapies.
Bears say
Metsera Inc faces challenges with its lead compounds, TZP and MET-097i, which exhibit approximately one logarithmic reduction in potency compared to native GLP-1, potentially undermining their competitive edge against existing and emerging therapies. Additionally, the company’s reliance on comparators like Roche's CT-388, which displayed limited efficacy with significant tolerability issues, raises concerns about the relevance of their data and the feasibility of their product development strategy. Furthermore, the broader landscape for small to mid-cap biotechnology companies poses consistent risks, adding to Metsera's uncertain outlook as it attempts to scale its proprietary technologies and product portfolio.
This aggregate rating is based on analysts' research of Metsera Inc and is not a guaranteed prediction by Public.com or investment advice.
Metsera Inc (MTSR) Analyst Forecast & Price Prediction
Start investing in Metsera Inc (MTSR)
Order type
Buy in
Order amount
Est. shares
0 shares